A recent study confirms that the 100-year-old BCG vaccine does not protect against COVID-19, challenging early assumptions ...

Following the Bacillus Calmette-Guérin shortage, the first patient with bladder cancer has been dosed with recombinant ...

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced U.S. Urology Partners, one of the nation’s ...

BLADDER cancer is classified as either non-muscle invasive bladder cancer (NMIBC) or muscle-invasive bladder cancer (MIBC) ...

ImmunityBio (IBRX) announced U.S. Urology Partners, one of the nation’s largest independent providers of urology and related specialty ...

BCG highlights how governments are reshaping energy policies to balance sustainability, security and affordability, focusing ...

Nadofaragene firadenovec intravesical gene therapy continues to show promise in treating BCG-unresponsive NMIBC bladder cancer.

According to the company, the new, 225,000-square-foot expansion is a "crucial component" of a more than $12 billion infusion ...

ImmunityBio (IBRX) faces operational, financial, and competitive challenges, impacting its growth prospects despite Anktiva's ...

An expanded access program evaluating cretostimogene grenadenorepvec was highlighted during the 25th Annual Meeting of the ...

GenAI could be India’s next trillion-dollar opportunity, transforming IT services the way cloud computing once did. But India ...